Asian Myeloma Network

Established by the International Myeloma Foundation (IMF) at a meeting in Singapore in 2011, the Asian Myeloma Network^® (AMN) is the first of its kind in the region and is comprised of myeloma experts from China, Hong Kong, Malaysia, Taiwan, Japan, Philippines, Singapore, South Korea, Vietnam, and Thailand. The AMN has taken the lead in projects to assist IMF in providing physician education and patient support throughout Asia. Since its founding, the AMN has: created a unified database to assess the incidence of myeloma in Asian countries as a basis for establishing region-specific treatment management tools and strategies; launched and overseen clinical trials; enabled myeloma patients to gain access to the newest myeloma treatments; developed informational resource materials in local languages, especially for patients and caregivers; and engaged in collaborative studies.

Asian Myeloma Network (AMN) History

On March 17, 2011, the International Myeloma Foundation (IMF) established the Asian Myeloma Network (AMN) at a meeting in Singapore. Comprised of myeloma experts from China, Hong Kong, Malaysia,Taiwan, Japan, South Korea, Singapore, and Thailand, the IMF Asian Myeloma Network — the first of its kind in the region — has taken the lead in projects to assist IMF in providing physician education and patient support throughout Asia. Myeloma is a growing health problem in Asia, with an incidence that is approaching that in Western countries, but with a much larger population base.

Since its founding, the AMN has:

• Created a unified database to assess the incidence of myeloma in Asian countries as a basis for establishing region-specific treatment management tools and strategies.
• Launched and overseen clinical trials.
• Enabled myeloma patients to gain access to the newest myeloma treatments.
• Developed informational resource materials in local languages, especially for patients and caregivers.
• Engaged in collaborative studies.

Executive Committee

Wee Joo Chng, MD  — Chairperson of the AMN Executive Committee

Dr. Wee Joo Chng has been a Senior Consultant at the National University Cancer Institute, Singapore, part of the National University Health System, for almost two decades. He is an esteemed researcher in genomics, therapeutics and hematologic malignancies, with extensive experience in clinical practice, administration, and leadership. Dr. Chng is currently the Yong Loo Lin Professor in Medical Oncology, Vice President (Biomedical Sciences Research), and Senior Principal Investigator of the Cancer Science Institute of Singapore, at the National University of Singapore.

• Masahiro Abe
• Priscilla B. Caguioa
• Wenming Chen
• James Chim
• Gin Gin Gan
• Hiroshi Handa
• Jeffrey Huang
• Shinsuke Iida
• Hou Jian
• Jin Soek Kim
• Kihyun Kim
• Pankaj Malhotra
• Chandramouli Nagarajan
• Teeraya Puavilai
• Sen Mui Tan
• Rosalio P. Torres
• Uday Yanamandra

Executive Staff

• Daniel Navid
• Lisa Paik